Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience
Allogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many hematological malignancies. The graft versus leukemia effect, driven by donor T cells, plays a major role in its curative potential. This effect is sometimes very evident when patients with acute myeloid leukemia and myelodysplasia relapse after AHCT and are treated with donor lymphocyte infusions (DLIs). We retrospectively reviewed the charts of 64 patients who received DLI between 2012 and 2017 in our center.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Fouad Kerbage, Riwa Sakr, Valerie Lapierre, Kamelia Alexandrova, Tereza Coman, Severine Leroux, Nolwenn Lucas, Sylvain Pilorge, Eric Solary, Jean-henri Bourhis, Cristina Castilla-Llorente Tags: Review Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Transplants